Denis Macina (France)
Sanofi Vaccines Global MedicalAuthor Of 1 Presentation
EFFECTIVENESS OF PERTUSSIS VACCINES AMONG MEXICAN CHILDREN BETWEEN 2000 AND 2019
Abstract
Backgrounds:
Mexico’s early childhood pertussis immunization schedule consists of 4 doses, given at 2, 4, 6, and 18 months of age. A European-manufactured whole-cell pertussis (wP) vaccine was used in 2000-2007. Since 2008, 2-component acellular pertussis vaccines (2aP) have been used. This study estimated the effectiveness of 3 or 4 doses of the two vaccine types used in Mexico between 2000 and 2019.
Methods:
Pertussis cases among 6.5-48.5-month-olds reported over 2000-2019, their vaccination status and diagnosis confirmation type (clinical, laboratory or Epilink) were obtained from the Mexican National pertussis surveillance system. Vaccine coverage rates were derived from Mexico’s CeNSIA and CONAPO databases. Vaccine effectiveness (VE) was estimated using the screening method.
Results:
Comparable VE estimates were observed in the wP (2000-2007) and 2aP (2008-2019) vaccines periods, ranging from 94 to 97%, after either 3 or 4 doses, and regardless of the case-definition used (all notifications vs laboratory-confirmed only).
| Time Period (Vaccine-type) | Unvaccinated Cases (lab confirmed) | Fully Vaccinated Cases (lab confirmed) | Proportion of vaccinated cases (lab confirmed) | VCR DTP3 | VCR DTP4 | All Cases VE (95%CI) | Lab-confirmed Cases VE (95%CI) | |
| 6.5-18.5 months Cases (3vs0 doses) | 2000-2007(wP) | 54(11) | 57(9) | 0.51(0.45) | 85.18% | - | 96.41%(94.72-97.56) | 97.31%(93.34-98.91) |
| 2008-2019(2aP) | 606(384) | 496(206) | 0.45(0.35) | 82.43% | - | 95.68%(95.12-96.17) | 97.19%(96.66-97.63) | |
| 18.5-48.5 months Cases (4vs0 doses) | 2000-2007(wP) | 17(3) | 11(3) | 0.61(0.50) | - | 81.66% | 97.25%(94.10-98.71) | 96.36%(81.92-99.27) |
| 2008-2019(2aP) | 129(81) | 133(67) | 0.49(.45) | - | 78.64% | 93.98%(92.33-95.28) | 95.19%(93.34-96.52) |
Conclusions/Learning Points:
Over the 11-year period of their use, the pentavalent and hexavalent 2aP vaccines used in Mexico demonstrated as strong protective effectiveness as the previously used wP vaccine, ensuring protection from pertussis among vaccinated children at least up to the age of a scheduled school-entry booster. Maintaining high vaccination coverage rates is essential in preventing and controlling pertussis.
Presenter of 1 Presentation
EFFECTIVENESS OF PERTUSSIS VACCINES AMONG MEXICAN CHILDREN BETWEEN 2000 AND 2019
Abstract
Backgrounds:
Mexico’s early childhood pertussis immunization schedule consists of 4 doses, given at 2, 4, 6, and 18 months of age. A European-manufactured whole-cell pertussis (wP) vaccine was used in 2000-2007. Since 2008, 2-component acellular pertussis vaccines (2aP) have been used. This study estimated the effectiveness of 3 or 4 doses of the two vaccine types used in Mexico between 2000 and 2019.
Methods:
Pertussis cases among 6.5-48.5-month-olds reported over 2000-2019, their vaccination status and diagnosis confirmation type (clinical, laboratory or Epilink) were obtained from the Mexican National pertussis surveillance system. Vaccine coverage rates were derived from Mexico’s CeNSIA and CONAPO databases. Vaccine effectiveness (VE) was estimated using the screening method.
Results:
Comparable VE estimates were observed in the wP (2000-2007) and 2aP (2008-2019) vaccines periods, ranging from 94 to 97%, after either 3 or 4 doses, and regardless of the case-definition used (all notifications vs laboratory-confirmed only).
| Time Period (Vaccine-type) | Unvaccinated Cases (lab confirmed) | Fully Vaccinated Cases (lab confirmed) | Proportion of vaccinated cases (lab confirmed) | VCR DTP3 | VCR DTP4 | All Cases VE (95%CI) | Lab-confirmed Cases VE (95%CI) | |
| 6.5-18.5 months Cases (3vs0 doses) | 2000-2007(wP) | 54(11) | 57(9) | 0.51(0.45) | 85.18% | - | 96.41%(94.72-97.56) | 97.31%(93.34-98.91) |
| 2008-2019(2aP) | 606(384) | 496(206) | 0.45(0.35) | 82.43% | - | 95.68%(95.12-96.17) | 97.19%(96.66-97.63) | |
| 18.5-48.5 months Cases (4vs0 doses) | 2000-2007(wP) | 17(3) | 11(3) | 0.61(0.50) | - | 81.66% | 97.25%(94.10-98.71) | 96.36%(81.92-99.27) |
| 2008-2019(2aP) | 129(81) | 133(67) | 0.49(.45) | - | 78.64% | 93.98%(92.33-95.28) | 95.19%(93.34-96.52) |
Conclusions/Learning Points:
Over the 11-year period of their use, the pentavalent and hexavalent 2aP vaccines used in Mexico demonstrated as strong protective effectiveness as the previously used wP vaccine, ensuring protection from pertussis among vaccinated children at least up to the age of a scheduled school-entry booster. Maintaining high vaccination coverage rates is essential in preventing and controlling pertussis.